GlaxoSmithKline Pharmaceuticals Ltd buy melinda
Start price
15.10.17
/
50%
?15.93
Target price
06.11.17
€17.55
Performance (%)
10.16%
End price
06.11.17
€17.55
Summary
This prediction ended on 06.11.17 with a price of €17.55. The prediction had a final performance of 10.16%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | - | - | - | - |
| iShares Core DAX® | 1.085% | -1.655% | 13.297% | 57.692% |
| iShares Nasdaq 100 | -1.665% | -3.137% | 2.218% | 83.804% |
| iShares Nikkei 225® | 3.863% | 6.947% | 22.818% | 56.282% |
| iShares S&P 500 | 0.111% | -1.320% | 1.445% | 57.791% |
Comments by melinda for this prediction
In the thread GlaxoSmithKline Pharmaceuticals Ltd diskutieren
Ebola-Virus
Die Impfstoffkandidaten enthalten CAD3-EBOZ, mitentwickelt von NIAID und Glaxosmithkline (GSK) und RVSV-ZEBOV, die ursprünglich von Wissenschaftlern der Public Health Agency of Canada und ist jetzt lizenziert Merck Sharp entwickelt wurde & Dohme Corp. GSK und Merck Impfstoffe für die Studie zur Verfügung gestellt.
Stopped prediction by melinda for GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd
Start price
Target price
Perf. (%)
?1,225.5
15.10.17
15.10.17
€1,350.0
06.11.17
06.11.17
10.16%
06.11.17
06.11.17
